JP2021528421A5 - - Google Patents

Info

Publication number
JP2021528421A5
JP2021528421A5 JP2020570916A JP2020570916A JP2021528421A5 JP 2021528421 A5 JP2021528421 A5 JP 2021528421A5 JP 2020570916 A JP2020570916 A JP 2020570916A JP 2020570916 A JP2020570916 A JP 2020570916A JP 2021528421 A5 JP2021528421 A5 JP 2021528421A5
Authority
JP
Japan
Prior art keywords
mer
pharmaceutical composition
chondroitin sulfate
composition according
skeleton
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020570916A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021528421A (ja
JP7538724B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/037993 external-priority patent/WO2019246264A1/en
Publication of JP2021528421A publication Critical patent/JP2021528421A/ja
Publication of JP2021528421A5 publication Critical patent/JP2021528421A5/ja
Application granted granted Critical
Publication of JP7538724B2 publication Critical patent/JP7538724B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020570916A 2018-06-20 2019-06-19 細胞保護の方法と組成物 Active JP7538724B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862687540P 2018-06-20 2018-06-20
US62/687,540 2018-06-20
PCT/US2019/037993 WO2019246264A1 (en) 2018-06-20 2019-06-19 Cell protective methods and compositions

Publications (3)

Publication Number Publication Date
JP2021528421A JP2021528421A (ja) 2021-10-21
JP2021528421A5 true JP2021528421A5 (cg-RX-API-DMAC7.html) 2022-06-27
JP7538724B2 JP7538724B2 (ja) 2024-08-22

Family

ID=68984366

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020570916A Active JP7538724B2 (ja) 2018-06-20 2019-06-19 細胞保護の方法と組成物

Country Status (5)

Country Link
US (2) US11633424B2 (cg-RX-API-DMAC7.html)
EP (1) EP3810152A4 (cg-RX-API-DMAC7.html)
JP (1) JP7538724B2 (cg-RX-API-DMAC7.html)
CN (1) CN112437667B (cg-RX-API-DMAC7.html)
WO (1) WO2019246264A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018165656A1 (en) 2017-03-10 2018-09-13 The University Of North Carolina At Chapel Hill Short-acting heparin-based anticoagulant compounds and methods
US11993627B2 (en) 2017-07-03 2024-05-28 The University Of North Carolina At Chapel Hill Enzymatic synthesis of homogeneous chondroitin sulfate oligosaccharides
US11865137B2 (en) 2017-11-03 2024-01-09 The University Of North Carolina At Chapel Hill Sulfated oligosaccharides having anti-inflammatory activity
WO2021097345A1 (en) 2019-11-13 2021-05-20 The University Of North Carolina At Chapel Hill Heparan sulfate (hs) oligosaccharides effect in liver ischemia reperfusion injury
CN116254296A (zh) * 2023-03-27 2023-06-13 中国科学院微生物研究所 利用昆虫细胞杆状病毒表达系统表达硫酸软骨素修饰酶的方法及应用
CN116254295A (zh) * 2023-03-27 2023-06-13 中国科学院微生物研究所 利用昆虫细胞杆状病毒表达系统表达软骨素6-o-硫酸转移酶的方法及应用

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
IT1232939B (it) 1987-11-06 1992-03-10 Opocrin Spa Eparan solfato caratterizzato da elevata attivita' antitrombotica, elevata biodisponibilita', assenza di attivita' anticoagulante; suo processo di estrazione da organi e da tessuti e relative composizioni farmaceutiche
US4865870A (en) 1988-07-07 1989-09-12 Becton, Dickinson And Company Method for rendering a substrate surface antithrombogenic
PT93847A (pt) 1989-04-24 1990-11-20 Harvard College Processo para a preparacao de oligossacaridos de baixo peso molecular derivados de heparina ou de sulfato de heparano despolimerizados e de composicoes farmaceuticas que os contem
US5378829A (en) 1990-04-23 1995-01-03 Akzo N.V. Sulfated glycosaminoglycanoid derivatives of the heparin and heparan sulfate type
WO1993005167A1 (en) 1991-09-06 1993-03-18 Children's Medical Center Corporation Cell-type specific heparan sulfate proteoglycans and their uses
IT1260137B (it) 1992-04-17 1996-03-28 Alfa Wassermann Spa Glicosaminoglicani semisintetici a struttura eparinica od eparanica modificati nella posizione 2 dell'acido alfa-l-iduronico-2-0-solfato
JP3818676B2 (ja) 1994-07-22 2006-09-06 生化学工業株式会社 ヘパラン硫酸6−o−硫酸基転移酵素
IT1271057B (it) 1994-11-04 1997-05-26 Inalco Spa Polisaccaridi aventi un elevato contenuto di acido iduronico
JP3672359B2 (ja) 1995-07-24 2005-07-20 生化学工業株式会社 ヘパラン硫酸 2−o−硫酸基転移酵素
CA2233343A1 (en) 1995-09-29 1997-04-03 Biomarin Pharmaceutical, Inc. Use of heparinases to decrease inflammatory responses
US5935824A (en) 1996-01-31 1999-08-10 Technologene, Inc. Protein expression system
US6861254B1 (en) 1997-10-24 2005-03-01 Massachusetts Institute Of Technology Heparan sulfate D-glucosaminyl 3-O-sulfotransferases, and uses therefor
US8088604B2 (en) 1998-04-02 2012-01-03 The Board Of Regents Of The University Of Oklahoma Production of defined monodisperse heparosan polymers and unnatural polymers with polysaccharide synthases
US7307159B2 (en) 2001-05-08 2007-12-11 The Board Of Regents Of The University Of Oklahoma Heparin/heparosan synthase from P. multocida and methods of making and using same
US6624141B1 (en) 1999-03-17 2003-09-23 The Regents Of The University Of Michigan Protamine fragment compositions and methods of use
US6255088B1 (en) 1999-05-11 2001-07-03 The Scripps Research Institute Enzymatic sulfation of biomolecules
US7101859B2 (en) * 2000-01-10 2006-09-05 Yissum Research Development Company Of The Hebrew University Of Jerusalem Use of lipid conjugates in the treatment of diseases
CN100369925C (zh) 2000-07-07 2008-02-20 生化学工业株式会社 透明质酸低聚糖级分及含有该物质的药品
CA2441984A1 (en) 2001-03-28 2002-10-10 Massachusetts Institute Of Technology Methods of 6-o-sulfating polysaccharides and 6-o-sulfated polysaccharide preparations
PT2070939E (pt) 2001-05-25 2014-06-09 Univ Duke Moduladores de agentes farmacológicos
WO2003018598A2 (en) 2001-08-30 2003-03-06 University College Dublin Monosaccharide derivatives
WO2004005475A2 (en) 2002-07-05 2004-01-15 University Of North Carolina At Chapel Hill Purified and isolated heparan sulfate 3-o-sulfotransferase isoform 5 nucleic acids and polypeptides and therapeutic and screening methods using same
GB0216861D0 (en) 2002-07-19 2002-08-28 Univ Birmingham Saccharide libraries
AU2003262794A1 (en) 2002-08-23 2004-03-11 Neose Technologies, Inc. Total synthesis of heparin
WO2005014619A2 (en) 2003-03-28 2005-02-17 Thomas Jefferson University Heparin-binding peptides and uses thereof
EP1529785B1 (en) 2003-10-24 2011-03-16 3M Innovative Properties Company Aqueous dispersions of polytetrafluoroethylene particles
US7655445B2 (en) 2003-11-12 2010-02-02 Massachusetts Institute Of Technology Methods for synthesis of sulfated saccharides
EP1761550A2 (en) * 2004-05-26 2007-03-14 California Institute of Technology Small molecule stimulators of neuronal growth
WO2006015171A2 (en) * 2004-07-28 2006-02-09 The Texas A & M University System Use of glycosoaminoglycans for the prevention and treatment of sepsis
EP1885865A4 (en) 2005-05-12 2010-12-22 Univ North Carolina ENZYMATIC SYNTHESIS OF SULFATED POLYSACCHARIDES
AU2007267561B2 (en) 2006-05-25 2012-05-17 Momenta Pharmaceuticals, Inc. Low molecular weight heparin composition and uses thereof
US20090035787A1 (en) 2007-07-23 2009-02-05 The University Of North Carolina At Chapel Hill Enzymatic synthesis of sulfated polysaccharides without iduronic acid residues
EP2205642B1 (en) 2007-11-02 2016-01-27 Momenta Pharmaceuticals, Inc. Non-anticoagulant polysaccharide compositions
CA2743496C (en) 2008-11-14 2018-03-27 Portola Pharmaceuticals, Inc. Antidotes for factor xa inhibitors and methods of using the same in combination with blood coagulating agents
US8993536B2 (en) * 2009-02-02 2015-03-31 Otsuka Chemical Co., Ltd. Low-molecular polysulfated hyaluronic acid derivative and medicine containing same
MX2011010616A (es) 2009-04-09 2012-03-14 Univ North Carolina Metodos para tratar edema relacionado a isquemia-reperfusion.
US20110054236A1 (en) 2009-08-25 2011-03-03 The Regents Of The University Of Michigan Compositions and methods for targeting tumors
WO2011038047A1 (en) 2009-09-23 2011-03-31 Momenta Pharmaceuticals, Inc. Methods of treatment with a low molecular weight heparin composition
DK2646037T3 (en) * 2010-12-01 2019-03-04 Univ Australian National use of polyanions to inhibit the cytotoxic activity of histones in the treatment of sepsis
WO2012088416A2 (en) 2010-12-23 2012-06-28 The University Of North Carolina At Chapel Hill Chemoenzymatic synthesis of structurally homogeneous ultra-low molecular weight heparins
WO2012116048A1 (en) 2011-02-22 2012-08-30 Rensselaer Polytechnic Institute Single step heparosan n-deacetylation and depolymerization for making bioengineered heparin
US8519189B2 (en) 2011-06-01 2013-08-27 University Of British Columbia Polymers for reversing heparin-based anticoagulation
WO2014135694A1 (en) 2013-03-08 2014-09-12 Csl Behring Ag Treatment and prevention of remote ischemia-reperfusion injury
JP6670235B2 (ja) 2013-06-17 2020-03-18 ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒルThe University Of North Carolina At Chapel Hill 可逆的ヘパリン分子、その製法及びその使用方法
WO2018165656A1 (en) 2017-03-10 2018-09-13 The University Of North Carolina At Chapel Hill Short-acting heparin-based anticoagulant compounds and methods
US11993627B2 (en) 2017-07-03 2024-05-28 The University Of North Carolina At Chapel Hill Enzymatic synthesis of homogeneous chondroitin sulfate oligosaccharides
US11865137B2 (en) 2017-11-03 2024-01-09 The University Of North Carolina At Chapel Hill Sulfated oligosaccharides having anti-inflammatory activity
WO2021097345A1 (en) 2019-11-13 2021-05-20 The University Of North Carolina At Chapel Hill Heparan sulfate (hs) oligosaccharides effect in liver ischemia reperfusion injury

Similar Documents

Publication Publication Date Title
JP2025037925A5 (cg-RX-API-DMAC7.html)
JP2024516371A5 (cg-RX-API-DMAC7.html)
JP2021530451A5 (cg-RX-API-DMAC7.html)
JP2005534660A5 (cg-RX-API-DMAC7.html)
KR930016389A (ko) No 신타제 및 시클로옥시게나제의 이중 억제제, 이들의 제조방법 및 이들을 함유하는 치료 조성물
JP2006505543A5 (cg-RX-API-DMAC7.html)
JP2009511508A5 (cg-RX-API-DMAC7.html)
JP2008508360A5 (cg-RX-API-DMAC7.html)
JP2008510828A5 (cg-RX-API-DMAC7.html)
JP2005523922A5 (cg-RX-API-DMAC7.html)
JP2008503515A5 (cg-RX-API-DMAC7.html)
RU2010133903A (ru) Способ и промежуточные соединения для получения производных 5-бифенил-4-ил-2-метилпентановой кислоты
JP2009536221A5 (cg-RX-API-DMAC7.html)
JP2010501474A5 (cg-RX-API-DMAC7.html)
RU2010107684A (ru) Конденсированные гетероциклы
JP2024532768A5 (cg-RX-API-DMAC7.html)
TW200635585A (en) Monocyclic substituted methanones
JP2009520695A5 (cg-RX-API-DMAC7.html)
CA2634005A1 (en) N-hydroxyamide derivatives possessing antibacterial activity
JP2013513607A5 (cg-RX-API-DMAC7.html)
JP2011528662A5 (cg-RX-API-DMAC7.html)
JP2023506005A5 (cg-RX-API-DMAC7.html)
RU2007124202A (ru) Новые соединения, обладающие функцией антикоагулянтов, фармацевтические компании на их основе для лечения тромботических состояний и плазмозамещающий раствор для коррекции гиперкоагуляционных нарушений при гемодилюции
JP2013514384A5 (cg-RX-API-DMAC7.html)
JP2012524070A5 (cg-RX-API-DMAC7.html)